Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 5, 2006, Pages 417-420

  Flight, Simone M ^a,d   Masci, Paul P ^a   Lavin, Martin F ^b   Gaffney, Patrick J ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Fibrinolysis; Plasminogen activation; Porcine; Thromboelastography

Indexed keywords

ALTEPLASE; FIBRIN; PLASMIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

ANALYZER; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; EUGLOBULIN LYSIS TEST; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HUMAN; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SWINE; THROMBOELASTOGRAPHY;

ANIMALS; ENZYME ACTIVATION; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; MODELS, ANIMAL; PLASMINOGEN; RECOMBINANT PROTEINS; SERUM GLOBULINS; SWINE; THROMBELASTOGRAPHY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33745425332     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000233374.79593.57     Document Type: Article

References (28)

1. Orchard MA, Goodchild CS, Prentice CR, Davies JA, Benoit SE, Creighton-Kemsford LJ, et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993; 85:533-541.
2. Gaffney PJ. Molecular aspects of fibrinolysis. Ann NY Acad Sci 1981; 370:551-567.
3. Collen D, Verstraete M. Molecular biology of human plasminogen. II. Metabolism in physiological and some pathological conditions in man. Thromb Diath Haemorrh 1975; 34:403-408.
4. Violand BN, Castellino FJ. Mechanism of the urokinase-catalyzed activation of human plasminogen. J Biol Chem 1976; 251:3906-3912.
5. Walther PJ, Steinman HM, Hill RL, McKee PA. Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide. J Biol Chem 1974; 249:1173-1181.
6. Wiman B. Primary structure of peptides released during activation of human plasminogen by urokinase. Eur J Biochem 1973; 39:1-9.
7. Wiman B, Wallen P. Structural relationship between 'glutamic acid' and 'lysine' forms of human plasminogen and their interaction with the NH2-terminal activation peptide as studied by affinity chromatography. Eur J Biochem 1975; 50:489-494.
8. Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242:2333-2342.
9. Miles LA, Castellino FJ, Gong Y. Critical role for conversion of gluplasminogen to Lys-plasminogen for optimal stimulation of plasminogen activation on cell surfaces. Trends Cardiovasc Med 2003; 13:21-30.
10. Gaffney PJ, Longstaff C. Fibrinolysis - a review. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone; 1993, pp. 549-573.
11. Singer AJ, McClain SA, Katz A. A porcine epistaxis model: hemostatic effects of octylcyanoacrylate. Otolaryngol Head Neck Surg 2004; 130:553-557.
12. Takasu A, Norio H, Sakamoto T, Okada Y. Surgical treatment of liver injury with microwave tissue coagulation: an experimental study. J Trauma 2004; 56:984-989.
13. Castellino FJ, Urano T, de Serrano V, Morris JP, Chibber BA. Control of human plasminogen activation. Haemostasis 1988; 18:15-23.
14. Parker SJ, Brown D, Hill PF, Watkins PE. Fibrinogen-impregnated collagen as a combined haemostatic agent and antibiotic delivery system in a porcine model of splenic trauma. Eur J Surg 1999; 165:609-614.
15. Vang SN, Stammers AH, Mejak BL, Rauch ED, Viessman TW, Bruda NL, et al. Co-administration of aprotinin and epsilon-aminocaproic acid during cardiopulmonary bypass in a swine model. J Extra Corpor Technol 2000; 32:196-206.
16. Riess FC, Potzsch B, Behr I, Jager K, Rossing R, Bleese N, et al. Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model. Eur J Cardiothorac Surg 1997; 11:739-745.
17. Hughes GC, Post MJ, Simons M, Annex BH. Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. J Appl Physiol 2003; 94:1689-1701.
18. Machovich R, Litwiller RD, Owen WG. Requirement of zymogen modification for activation of porcine plasminogen. Biochemistry 1992; 31:11558-11561.
19. Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170:1095-1096.
20. Brennan SO, Hammonds B, George PM. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 Val → Asp). J Clin Invest 1995; 96:2854-2858.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
22. Kaulla von KN, Schultz R. Method for evaluation of human fibrinolysis. Am J Clin Pathol 1958; 19:619-625.
23. Hartert H. Blutgerninnungstudien mit der thromboeslastographic, einen neven untersuchingsver fahren. Klin Wochenschr 1948; 16:257-260.
24. Machovich R, Owen WG. 6-aminohexanoate and chloride ion in the activation by urokinase of porcine plasminogens. Biochim Biophys Acta 1990; 1040:109-111.
25. Cullen P, Baetta R, Bellosta S, Bernini F, Chinetti G, Cignarella A, et al. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol 2003; 23:535-542.
26. Schaar JA, de Korte CL, Mastik F, Baldewsing R, Regar E, de Feyter P, et al. Intravascular palpography for high-risk vulnerable plaque assessment. Herz 2003; 28:488-495.
27. Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 2002; 200:639-646.
28. Samama CM, Mazoyer E, Bruneval P, Ciostek P, Bonnin P, Bonneau M, et al. Aprotinin could promote arterial thrombosis in pigs: a prospective randomized, blind study. Thromb Haemost 1994; 71:663-669.